Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

医学 无容量 打开标签 肿瘤科 肺癌 内科学 化疗 临床研究阶段 临床试验 新辅助治疗 癌症 乳腺癌 免疫疗法
作者
Mariano Provencio,Ernest Nadal,Amelia Insa,M.R. García-Campelo,Joaquín Casal‐Rubio,Manuel Dómine,Margarita Majem,Delvys Rodríguez‐Abreu,Alex Martínez‐Martí,Javier de Castro,Manuel Cobo,Guillermo López-Vivanco,E. del Barco,Reyes Bernabé,Núria Viñolas,Isidoro Barneto Aranda,Santiago Viteri,Eva Pereira,Ana Royuela,Marta Casarrubios
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:21 (11): 1413-1422 被引量:952
标识
DOI:10.1016/s1470-2045(20)30453-8
摘要

Background Non-small-cell lung cancer (NSCLC) is terminal in most patients with locally advanced stage disease. We aimed to assess the antitumour activity and safety of neoadjuvant chemoimmunotherapy for resectable stage IIIA NSCLC. Methods This was an open-label, multicentre, single-arm phase 2 trial done at 18 hospitals in Spain. Eligible patients were aged 18 years or older with histologically or cytologically documented treatment-naive American Joint Committee on Cancer-defined stage IIIA NSCLC that was deemed locally to be surgically resectable by a multidisciplinary clinical team, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients received neoadjuvant treatment with intravenous paclitaxel (200 mg/m2) and carboplatin (area under curve 6; 6 mg/mL per min) plus nivolumab (360 mg) on day 1 of each 21-day cycle, for three cycles before surgical resection, followed by adjuvant intravenous nivolumab monotherapy for 1 year (240 mg every 2 weeks for 4 months, followed by 480 mg every 4 weeks for 8 months). The primary endpoint was progression-free survival at 24 months, assessed in the modified intention-to-treat population, which included all patients who received neoadjuvant treatment, and in the per-protocol population, which included all patients who had tumour resection and received at least one cycle of adjuvant treatment. Safety was assessed in the modified intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT03081689, and is ongoing but no longer recruiting patients. Findings Between April 26, 2017, and Aug 25, 2018, we screened 51 patients for eligibility, of whom 46 patients were enrolled and received neoadjuvant treatment. At the time of data cutoff (Jan 31, 2020), the median duration of follow-up was 24·0 months (IQR 21·4–28·1) and 35 of 41 patients who had tumour resection were progression free. At 24 months, progression-free survival was 77·1% (95% CI 59·9–87·7). 43 (93%) of 46 patients had treatment-related adverse events during neoadjuvant treatment, and 14 (30%) had treatment-related adverse events of grade 3 or worse; however, none of the adverse events were associated with surgery delays or deaths. The most common grade 3 or worse treatment-related adverse events were increased lipase (three [7%]) and febrile neutropenia (three [7%]). Interpretation Our results support the addition of neoadjuvant nivolumab to platinum-based chemotherapy in patients with resectable stage IIIA NSCLC. Neoadjuvant chemoimmunotherapy could change the perception of locally advanced lung cancer as a potentially lethal disease to one that is curable. Funding Bristol-Myers Squibb, Instituto de Salud Carlos III, European Union's Horizon 2020 research and innovation programme.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
科目三的应助被自觉觅柔采纳,获得10
1秒前
彭于晏的应助被科研通管家采纳,获得10
1秒前
彭于晏的应助被科研通管家采纳,获得10
1秒前
hermit的应助被科研通管家采纳,获得50
2秒前
2秒前
Orange的应助被科研通管家采纳,获得10
2秒前
领导范儿的应助被科研通管家采纳,获得10
2秒前
万能图书馆的应助被独特幻然采纳,获得10
2秒前
2秒前
gzh完成签到,获得积分10
2秒前
领导范儿的应助被科研通管家采纳,获得10
2秒前
CipherSage的应助被科研通管家采纳,获得10
2秒前
Owen的应助被科研通管家采纳,获得10
2秒前
3秒前
3秒前
3秒前
coolru的应助被科研通管家采纳,获得10
3秒前
彭于晏的应助被科研通管家采纳,获得10
3秒前
星辰大海的应助被科研通管家采纳,获得10
3秒前
秋风的应助被科研通管家采纳,获得20
3秒前
英姑的应助被科研通管家采纳,获得10
3秒前
4秒前
4秒前
4秒前
小呆橘发布了新的文献求助10
5秒前
阡陌完成签到,获得积分10
6秒前
徐徐发布了新的文献求助10
6秒前
ruby完成签到,获得积分10
6秒前
7秒前
神勇千凝完成签到,获得积分10
8秒前
8秒前
MengYX完成签到,获得积分10
8秒前
9秒前
black27发布了新的文献求助10
9秒前
9秒前
wjq1106完成签到,获得积分10
9秒前
69完成签到,获得积分10
10秒前
Firsterchao完成签到,获得积分0
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191414
求助须知:如何正确求助?哪些是违规求助? 9578277
关于积分的说明 21857909
捐赠科研通 7790787
什么是DOI,文献DOI怎么找? 3436640
关于科研通互助平台的介绍 2560362
邀请新用户注册赠送积分活动 2483366